538 completed, 164 recruiting, 90 terminated, 70 unknown. 1003 Phase 1, 311 Phase 2.
Follow Connective Tissue Diseases: new trials by email Literature Review of Connective Tissue Diseases trials Research Report on Connective Tissue Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabichromene Safety in Rheumatoid Arthritis Cannabichromene - Arthritis, Rheumatoid | Phase 1 / Phase 2 | Withdrawn | Crystal Lederhos Smith | 2028-07-15 | 2026-09-23 | |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus | Phase 1 | Withdrawn | Caribou Biosciences, Inc. | 2027-12-01 | 2025-09-19 | |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis | Phase 1 | Not yet recruiting | AbelZeta Inc. | 12 | 2027-03-01 | 2026-10-13 |
| Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB rAAV9-CMV-hNAGLUop - Sanfilippo Syndrome (MPS III) | Phase 1 / Phase 2 | Not yet recruiting | NeuroGT | 9 | 2027-01-18 | 2026-09-14 |
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI) Bone marrow-derived mesenchymal stromal cells (MSCs) - Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III | Phase 1 / Phase 2 | Not yet recruiting | Emory University | 12 | 2027-01-01 | 2026-05-08 |
| An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 36 | 2027-01-01 | 2026-11-12 |
| Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases HN2302 Injection - Autoimmune Disease, Systemic Lupus Erythematosus | Phase 1 | Not yet recruiting | Shenzhen MagicRNA Biotechnology Co., Ltd | 12 | 2026-12-31 | 2026-08-12 |
| Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases anti-CD19 CAR-T cells - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 1 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 6 | 2026-12-01 | 2026-09-02 |
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis hUC-MSC suspension, Placebo - Rheumatoid Arthritis | Phase 1 | Not yet recruiting | Baylx Inc. | 16 | 2026-12-01 | 2025-12-23 |
| An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE) DKB903 - Rheumatoid Arthritis and Systemic Lupus Erythematosus | Phase 1 | Not yet recruiting | Novartis Pharmaceuticals | 90 | 2026-12-01 | 2026-11-06 |
| A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases QLS2416 Injection - Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA) | Phase 1 | Not yet recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | 76 | 2026-12-01 | 2026-10-30 |
| A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Not yet recruiting | Pfizer | 54 | 2026-11-19 | 2026-10-01 |
| A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol Dapirolizumab pegol (DZP) - Systemic Lupus Erythematosus | Phase 1 | Not yet recruiting | UCB Biopharma SRL | 25 | 2026-11-15 | 2026-11-13 |
| To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Cevostamab, Tocilizumab - Lupus Erythematosus, Systemic | Phase 1 | Recruiting | Genentech, Inc. | 46 | 2026-11-02 | 2026-11-05 |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| R-2487 in Patients With Sjogren's Syndrome (SjD) R-2487 - Sjogren's Syndrome, Sjögren | Phase 1 | Not yet recruiting | Rise Therapeutics LLC | 36 | 2026-11-01 | 2026-11-06 |
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV) Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFS - Systemic Lupus Erythematosus | Phase 1 | Not yet recruiting | AstraZeneca | 92 | 2026-10-30 | 2026-07-07 |
Showing 20 of 1003. Sign in to see all of them.
Arthritis, Rheumatoid (386) · Lupus Erythematosus, Systemic (288) · Scleroderma, Systemic (107) · Lupus Nephritis (71) · Autoimmune Diseases (61) · Scleroderma, Diffuse (48) · Sjogren's Syndrome (45) · Myositis (39) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (29) · Dermatomyositis (29) · Mucopolysaccharidosis I (28) · Arthritis (26) · Epidermolysis Bullosa Dystrophica (25) · Arthritis, Juvenile (24) · Inflammation (21)
Skin and Connective Tissue Diseases (999) · Immune System Diseases (721) · Autoimmune Diseases (660) · Musculoskeletal Diseases (520) · Joint Diseases (452) · Rheumatic Diseases (445) · Arthritis (432) · Skin Diseases (237) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (146) · Genetic Diseases, Inborn (123) · Nervous System Diseases (111) · Pathological Conditions, Signs and Symptoms (107) · Nutritional and Metabolic Diseases (91) · Pathologic Processes (91)
Cyclophosphamide (35) · fludarabine (29) · Methotrexate (25) · Rituximab (19) · tocilizumab (17) · Abatacept (16) · tofacitinib (14) · sarilumab (12) · belimumab (9) · Etanercept (7) · Saline Solution (7) · fostamatinib (7) · Iduronidase (6) · Injections (6) · Midazolam (6)
GlaxoSmithKline (31) · Bristol-Myers Squibb (29) · Pfizer (26) · Amgen (25) · AstraZeneca (23) · Novartis Pharmaceuticals (17) · Sanofi (12) · Eli Lilly and Company (11) · Hoffmann-La Roche (10) · Novo Nordisk A/S (10) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (9) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (9) · Chongqing Precision Biotech Co., Ltd (8) · Gilead Sciences (8) · National Institute of Allergy and Infectious Diseases (NIAID) (8)
United States (450) · China (173) · Germany (94) · United Kingdom (75) · Spain (73) · Australia (51) · France (49) · Poland (47) · Canada (43) · Netherlands (41) · South Korea (40) · Japan (34) · Belgium (28) · Italy (28) · Russia (26)
PMID 34628605, PMID 34741731, PMID 22547151, PMID 25421091, PMID 25749867, PMID 26138472, PMID 26290435, PMID 27099766, PMID 27112532, PMID 28143815, PMID 28925994, PMID 29526614, PMID 29776017, PMID 29976218, PMID 32453485, PMID 32816215, PMID 33127856, PMID 33506875, PMID 33687069, PMID 34347960, PMID 34870800, PMID 35835061, PMID 36109639, PMID 36299240, PMID 36526796, PMID 36600185, PMID 36601090, PMID 36931693, PMID 38258274, PMID 39454617, PMID 10415784, PMID 15324318, PMID 15807196, PMID 17425783, PMID 18250115, PMID 18459515, PMID 18468955, PMID 18534016, PMID 18759293, PMID 18786258, PMID 18986773, PMID 19146602, PMID 19180499, PMID 19208097, PMID 19273451, PMID 19587341, PMID 19948615, PMID 19950289, PMID 20112381, PMID 20131246
2015 (14), 2017 (12), 2023 (10), 2025 (10), 2009 (7), 2016 (6), 2008 (5), 2014 (5), 2018 (4), 2019 (4), R01AR056702 (2), 2004 (1), K23AR002187 (1), K23AR075874 (1), P01HL075462 (1)